Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety. (PubMed, J Hum Immun) - Oct 15, 2026 - P2/3 | "Clinically meaningful improvements in general health scores from the 36-Item Short Form Survey were observed. Overall, long-term use of leniolisib was generally well tolerated, and infections and IRT use reduced over time."
Journal • Cardiovascular • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Oncology • Respiratory Diseases • PIK3CD
|
|
Alanvin Orpia; Alessandro Plebani; Anna Shcherbina; Anna Šedivá; Antonio Trizzino; Anurag Relan; Catharina Schuetz; Elaine Kulm; Gulbu Uzel; Jason Bradt; Julia Körholz; V Koneti Rao; Vassilios Lougaris; Virgil A S H Dalm; Yulia Rodina; Yulia Zharankova
|